SGLT2 inhibitors and other guideline-directed medical therapies are recommended as first-line treatments for patients with heart failure and diabetes to reduce cardiovascular death and hospitalization.
This consensus statement provides updated recommendations for the screening, diagnosis, and pharmacological management of heart failure in patients with diabetes mellitus in Korea.
Diabetes mellitus is a major risk factor for the development of heart failure. Furthermore, the prognosis of heart failure is worse in patients with diabetes mellitus than in those without it. Therefore, early diagnosis and proper management of heart failure in patients with diabetes mellitus are important. This review discusses the current criteria for diagnosis and screening tools for heart failure and the currently recommended pharmacological therapies for heart failure. We also highlight the effects of anti-diabetic medications on heart failure.
Lee et al. (2023) conducted a review in Diabetes mellitus and Heart failure. Guideline-directed medical therapy (SGLT2 inhibitors, RAAS inhibitors, beta-blockers, MRAs) was evaluated. SGLT2 inhibitors and other guideline-directed medical therapies are recommended as first-line treatments for patients with heart failure and diabetes to reduce cardiovascular death and hospitalization.